Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 study of subcutaneous leuprolide acetate ovarian suppression in HR-positive, HER2-negative breast cancer
RBR-26m455fPhase 3Recruiting
- Sponsor
- Fundação do ABC
- Start
- Jul 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of leuprolide acetate, tamoxifen, letrozole, anastrozole and exemestane in breast cancer (2 arms), sponsored by Fundação do ABC. Primary endpoint: Not reported. Started Jul 2021; status: recruiting.
02
Drugs
leuprolide acetatetamoxifenletrozoleanastrozoleexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on RBR-26m455f.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-26m455f.